Listen to gastroenterologist Prof. Matthieu Allez in conversation with patient advocate Evelyn Gross, who has been diagnosed with UC and Crohn’s disease. They discuss the importance of incorporating the patient perspective and shared decision-making into daily clinical practice to provide a personalised approach to treatment decisions.
Job code: GL-IBD-NA-202112-00003
Date of preparation: December 2021
Professor Matthieu Allez
Saint-Louis Hospital, University of Paris, Paris, France
Matthieu Allez has served as consultant to Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Galapagos, Genentech, Gilead, IQVIA, Janssen, Novartis, Pfizer, Roche, Takeda. He has received grant support from Janssen, Takeda and Genentech/Roche, and speaker fees from Abbvie, Ferring Pharmaceuticals, Genentech, Janssen, Pfizer, Roche, Takeda and Tillotts Pharma
This pre-recorded meeting is sponsored by Galapagos NV
This information is intended for educational purposes only
Information within this meeting is not intended for promotion
This meeting may discuss off-label information regarding investigational molecules that have not been approved by any competent authorities such as the EMA or US FDA
The supporting scientific statements are factual as taken from abstracts, posters, publications and/or
regulatory documents and may not be used as claims of any kind
Views and opinions expressed in this meeting are those of the authors and are not necessarily of
In the absence of specific head-to-head trials, the therapies discussed here cannot be directly compared
Associate Professor of Gastroenterology at the University of Milan, Italy.
Flavio Caprioli's areas of expertise are pre-clinical research, mucosal and systemic immunology, and translational research in IBD. His PhD focussed on mechanisms of autocrine regulation of IL-21 in humans and the role of IL-21 in inducing naïve T cell polarisation towards effector Th17 lymphocytes. He has since studied the role of IL-21 as a promoter of systemic and intestinal inflammation and the neutralisation of this cytokine as a potential new therapeutic approach in autoimmune-related inflammatory diseases.
Consultant gastroenterologist at the University of Picardy Jules Verne and is Professor of Gastroenterology at Amiens University Hospital in Amiens, France.
Mathurin Fumery's research focusses on the epidemiology of IBD, and he is involved in the French IBD epidemiology registry, EPIMAD. Prof. Fumery has published extensively in the area of IBD, particularly around biologic treatments and population-based IBD epidemiology.
Head of Section of Gastroenterology at Hospital General Alicante, Spain.
Ana Gutiérrez is Vice President of the governing board of the Spanish IBD group GETECCU, where she also acts as the Director of training courses in IBD, and is the national representative of Spain within the European Crohn’s Colitis Organization. She gained a PhD and researched to a postdoctoral level at the University of Miguel Hernández, Spain, with a focus on the value of fibrolytic tests in patients with acute upper gastrointestinal haemorrhage.
Vice Director and Associate Professor at the Centre for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Taku Kobayashi is Director of the International Exchange Committee of the Japanese Society of IBD and a Clinical Research Committee member for the Asian Organization for Crohn’s and Colitis. He serves as a councillor for several Japanese gastroenterology societies. His current projects include global prospective randomised controlled trials and the development of prospective registries of Japanese patients with IBD.
Clinical Lead for gastroenterology at the Royal Hospital, London, UK
Gareth Parkes’ interests include IBD clinical trials, the role of the microbiota and probiotics, and the use of technology in the IBD clinic. He has sat on the British Society of Gastroenterology IBD Committee and has a range of publications in the fields of IBD, gastrointestinal microbiota and irritable bowel syndrome. He is Co-founder and Medical Director of Ampersand Health, which developed the award-winning app ‘My IBD Care’, using digital technology and behavioural science to improve patients’ lives.
Director of the Department of Internal Medicine I and Head of the Institute of Clinical Molecular Biology at Kiel University
Stefan Schreiber gained his medical degree at the University of Hamburg. After two fellowships he joined the Department of Gastroenterology, Charité University Hospital. In 1996 he became Associate Professor at Christian-Albrechts-University. He became Full Professor of Medicine in 1999, and Director of the Department of Internal Medicine I and Head of the Institute of Clinical Molecular Biology in 2004 at Kiel University. His research interests span genetics & pathophysiology of intestinal inflammation, IBD therapy development and human ageing. He has authored >1000 original publications.
Head of the Department of Chronic Diseases and Metabolism at KU Leuven.
Séverine Vermeire trained at KU Leuven, the National University of Asuncion, Paraguay, the Wellcome Trust Centre for Human Genetics, Oxford, UK and the Montreal General Hospital, Canada. Since 2003, she has been a member of the Gastroenterology Department at University Hospitals Leuven and Professor of Medicine at KU Leuven. She became Head of the Department of Chronic Diseases and Metabolism at KU Leuven in 2016. Her work has led to >500 peer-reviewed articles and focusses on the role of the microbiome, genetic susceptibility in IBD and signatures predictive of therapy response.